Utilized for atopic dermatitis to manage skin inflammation and support lesion healing without steroid use.
Mechanism of Action
Pimecrolimus binds to the cytosolic protein FKBP-12 and inhibits calcineurin. This prevents the activation of T-lymphocytes and blocks the release of inflammatory cytokines, effectively reducing eczema symptoms locally.
Route of Administration
Topical
Onset Time
1 week
Duration
12–24 hours
Contraindications
Active skin infection, Hypersensitivity to pimecrolimus, Netherton's syndrome
Severe Adverse Events
Lymphoma risk, Skin cancer risk, Anaphylaxis — requires immediate medical attention
Common Side Effects
Burning, Stinging, Redness
Uncommon Side Effects
Folliculitis, Flu-like symptoms, Headache
Drug Interactions
Alcohol
Pregnancy Safety Warnings
FDA Category C: Use with caution. Breastfeeding: Compatible with caution; avoid applying to breast.
Age Restrictions
Safety and efficacy established in pediatric patients two years and older.
Information related to Pimecrolimus 1% is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
